Manon Berger

The GT4Health project, which aims to develop various disruptive technologies as solutions to major challenges in the gene therapy sector, is a multidisciplinary collaboration involving ten partners from five French-speaking Belgian universities (ULiège, ULB, UCLouvain, UNamur and UMons), including four from ULiège, as well as the CER Groupe research centre.

In this project, which brings together a network of multidisciplinary skills, viral and non-viral vectors will be used to develop innovative personalised therapeutic solutions, enabling researchers to tackle hereditary and serious chronic diseases and cancers by validating a variety of therapeutic objectives, ranging from relatively accessible liver targets to the pancreas.